Key Highlights
- Aspira Women’s Health (OTCQB: AWHL) and Cleveland Clinic have signed a Master Collaboration and License Agreement to jointly discover, validate, and commercialize next-generation AI-powered multiomic biomarkers for women’s health diagnostics.
- The partnership pairs Cleveland Clinic’s translational research depth and patient sample access with Aspira’s proprietary AI-driven analytics and nucleic acid detection infrastructure, building on proven traction in ovarian cancer diagnostics.
- The agreement lays a scalable, multi-phase foundation spanning biomarker discovery, data generation, IP collaboration, and clinical research, positioning both organizations for accelerated translational development and broader commercial expansion.
A Strategic Alliance Built for Scale Aspira Women’s Health and Cleveland Clinic have entered a comprehensive Master Collaboration and License Agreement designed to accelerate the discovery and validation of novel biomarker signatures. The agreement establishes a durable framework covering biomarker discovery, data generation, translational development, intellectual property collaboration, and clinical research, giving both organizations a long runway for expanding diagnostic applications across women’s health rather than pursuing a single, isolated project.
Combining Clinical Depth With AI-Driven Innovation The collaboration unites Cleveland Clinic’s clinical and translational research expertise, led by Dr. Kevin Elias, Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research, with Aspira’s AI-enabled multiomic platform under the direction of Chief Scientific Officer Dr. Todd Pappas. Dr. Elias points to encouraging early results in ovarian cancer diagnostics as a springboard for applying multiomic biomarkers and advanced AI analytics more broadly across women’s health, aiming to sharpen clinical decision-making with noninvasive tools.
Expanding Access to Drive Faster Validation A central goal of the partnership is broader access to patient samples and enhanced clinical validation capacity, both critical levers for moving promising biomarker candidates from discovery into real-world clinical use. By pairing Aspira’s scalable, highly specific nucleic acid detection infrastructure with Cleveland Clinic’s research network, the companies aim to shorten the path toward accelerated development and eventual commercialization of next-generation diagnostics.
Leadership Signals Confidence in the Platform’s Future Aspira CEO Mike Buhle described the agreement as a defining inflection point in the company’s strategy to build a category-leading women’s health diagnostics platform, following a year of investment in scientific and operational capabilities. SVP Michelle Snider added that the collaboration strengthens Aspira’s position at the intersection of women’s health, AI, and precision medicine, while Dr. Pappas framed the deal as evidence of a scalable scientific framework built to support multiple future diagnostic applications.
By
